A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma.

Trial Profile

A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs DI Leu16 IL2 (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov report.
    • 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top